Synonyms: BMN 111 | BMN-111 | Voxzogo®
vosoritide is an approved drug (EMA & FDA (2021))
Compound class:
Peptide
Comment: Vosoritide is a cyclic analogue of C-type natriuretic peptide (CNP) that has a longer half-life (duration of action) than the endogenous peptide [1]. It comprises the 37 C-terminal amino acids from human CNP with the addition of proline and glycine (PG) at its N-terminal.
Vosoritide represents a novel mechanism which has the potential to treat mutant fibroblast growth factor receptor 3-driven achondroplasia, by stimulating endochondral ossification and thereby ameliorating impaired bone growth [1-3]. |
Classification | |
Compound class | Peptide |
Approved drug? | Yes (EMA & FDA (2021)) |
International Nonproprietary Names | |
INN number | INN |
10022 | vosoritide |
Synonyms |
BMN 111 | BMN-111 | Voxzogo® |
Database Links | |
CAS Registry No. | 1480724-61-5 (source: WHO INN record) |
GtoPdb PubChem SID | 315661153 |
PubChem CID | 119058036 |
Search Google for chemical match using the InChIKey | IGYWDDBBJPSOTG-WBAGYEQSSA-N |
Search Google for chemicals with the same backbone | IGYWDDBBJPSOTG |
Search PubMed clinical trials | vosoritide |
Search PubMed titles | vosoritide |
Search PubMed titles/abstracts | vosoritide |
UniChem Compound Search for chemical match using the InChIKey | IGYWDDBBJPSOTG-WBAGYEQSSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | IGYWDDBBJPSOTG-WBAGYEQSSA-N |